Regulus Therapeutics

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

SAN DIEGO, Jan. 20, 2022 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company has completed a pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to obtain input from the FDA on pre-clinical, clinical and regulatory matters pertaining to the Company's next generation compound RGLS8429 as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 10-13, 2022.

Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development.

Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development

SAN DIEGO, Dec. 1, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced a presentation at the first annual Rare & Genetic Kidney Disease Drug Development Summit. In the presentation, Regulus summarized its ongoing efforts to therapeutically target microRNAs (miRs), small non-coding RNAs that play an important role in the regulation of gene expression and are known to be involved in the pathogenesis of numerous genetic kidney diseases representing significant unmet medical needs.

Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit

SAN DIEGO, Nov. 30, 2021 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the closing of its previously announced private placement of equity.

Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity

LA JOLLA, Calif., Nov. 24, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors.

Regulus Therapeutics Announces Private Placement of Equity

Regulus Therapeutics Inc. (RGLS) CEO Jay Hagan on Q3 2021 Results - Earnings Call Transcript

Regulus (RGLS) delivered earnings and revenue surprises of -42.86% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

SAN DIEGO, Nov. 10, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.  "We are pleased with the progress we have made in advancing our next generation candidate RGLS8429 as a potential treatment for ADPKD, as the compound has been shown to have the favorable properties of RGLS4326 without the limitations of the first-generation compound," commented Jay Hagan, CEO of Regulus Therapeutics.

Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights for the quarter ended September 30, 2021 on Wednesday, November 10, 2021, after the U.S. financial markets close.  The Company will host a conference call and live audio webcast on Wednesday, November 10, 2021 at 5:00 p.m.

Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call

Senmiao Technology

BIMI International Medical

Meten Holding Group Ltd.

TherapeuticsMD

Are these Webull penny stocks to buy or avoid right now? The post 5 Penny Stocks To Buy For Under $1 On Webull Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy For Under $1 On Webull Right Now

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for

Futu Holdings

Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward.

How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More

The stock price of Regulus Therapeutics Inc (NASDAQ: RGLS) fell over 20% pre-market today. This is why it happened.

RGLS Stock: Why It Substantially Fell Today

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application (IND); and subject to U.S. Food and Drug Administration (FDA) clearance, initiating a phase 1 study in the second quarter of 2022.

Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease

SAN DIEGO, Sept. 30, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that David Baltimore, Ph.D.

Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science

SAN DIEGO, Sept. 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C.

Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Regulus Therapeutics' (RGLS) CEO Jay Hagan on Q2 2021 Results - Earnings Call Transcript

Regulus (RGLS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Shares of Regulus Therapeutics (NASDAQ:RGLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 65.22% year over year to ($0.08), which were in line with the estimate of ($0.08).

Recap: Regulus Therapeutics Q2 Earnings

SAN DIEGO, Aug. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.  "The team at Regulus accomplished a lot over the last several months, including the achievement of several major milestones in our ADPKD program, the completion of meeting preparations with FDA and extending our cash runway into Q4 of next year," commented Jay Hagan, CEO of Regulus.

Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates

SAN DIEGO, Aug, 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights for the quarter ended June 30, 2021 on Tuesday, August 10, 2021, after the U.S. financial markets close.  The Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 5:00 p.m.

Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call

Cinedigm

Looking for popular penny stocks to watch? Check these 3 out The post 3 Popular Penny Stocks For Your August 2021 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Popular Penny Stocks For Your August 2021 Watchlist

Clear Channel Outdoor Holdings

Cocrystal Pharma

1847 GOEDEKER INC.

Greenpro Capital Corp

OPKO Health

Transocean

Staffing 360 Solutions

With July in full swing, here's 8 penny stocks that investors are watching right now The post 8 Hot Penny Stocks That You Should Add to Your July Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Hot Penny Stocks That You Should Add to Your July Watchlist

Regulus Therapeutics Inc (NASDAQ: RGLS) announced the presentation of additional data from the first cohort from Phase 1b trial of RGLS4326 for autosomal dominant polycystic kidney disease (ADPKD), as well as new preclinical data.  The data were shared at the PKD Connect Conference 2021.

News for Regulus Therapeutics Stock (RGLS)